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Some prednisone-resistant asthma patients respond to intramuscular triamcinolone
acetonide (TA). The use of TA has been questioned on the basis of its potential toxicity.
TA’s ratio of clinical efﬁcacy to systemic effects compared with oral prednisone has not
been clearly deﬁned.
We report the case of a prednisone-insensitive severe asthma patient with insulin-
dependent diabetes, hypertension and diabetic retinopathy treated with repeated sessions
of laser therapy. By daily monitoring the needs of insulin doses we compared the systemic
effects of prednisone and TA.
The analysis of the balance between systemic effects (insulin doses) and beneﬁcial effects
(PEF values) show that TA has a better beneﬁt/risk proﬁle than prednisone. The patient has
been followed up for 3 years and has received injections of TA repeated at intervals
ranging from 21 to 60 days according to patient response and the evolution of PEF and
clinical symptoms. During this period the patient lost 3 kg of weight, while presenting
increased bone mineral density, normalized arterial tension, and improved proliferative
diabetic retinopathy.
The present case report shows that TA has a better beneﬁt/risk proﬁle than prednisone. TA
can be a valuable alternative in the control of some patients with severe prednisone-
resistant asthma.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
9813.Introduction
Response to glucocorticoids varies widely among asthma
patients, with some improving with small doses of inhaled
glucocorticoids, while others do not respond at all to high
doses of systemic glucocorticoids.1
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therapeutic challenge that at present has no efﬁcacious
alternative therapy.1
There is, however, an extended literature on the use of
the intramuscular injection of triamcinolone acetonide (TA)
in asthmatic patients who do not respond to prednisone. In
most of these studies, asthma patients insensitive to
prednisone show a very good response when treated
with AT.2–9
Two reasons are usually suggested to explain these
differences in the response: (1) the improvement after the
intramuscular injection of TA reﬂects nothing more than
improvement in adherence to the treatment, and (2)
triamcinolone is released from the acetonide or depot form
of the drug by a slow enzymatic process of deacetonization.
This results in a long pharmacological half-life with
remarkable therapeutical efﬁcacy but also with a high rate
of corticosteroid-related toxicities. Thus, the injection of TA
represents the use of a potent corticosteroid with pros and
cons similar to those observed with very high doses of
prednisone.10
Nevertheless, some observations do not appear to support
these arguments. In fact, prednisone-resistant asthma
patients who are good compliant subjects, respond to TA
without apparently suffering from an evident increase in
systemic side effects. On the contrary, these patients often
lose weight, their cushingoid appearance of the face
normalizes, and their blood pressure decreases, when they
are switched from high doses of daily prednisone to shots
of TA.7,9
These observations support the notion that TA may be
more effective than prednisone through a mechanism other
than improved compliance, as well as suggesting that its
therapeutic efﬁcacy is not necessarily associated with the
induction of more severe and unacceptable steroid-related
systemic side effects.
Systemic side effects of glucocorticoids can be assessed
by measuring cortisol levels at baseline and after cortico-
tropin. However, these methods are not very useful in the
daily monitoring of the systemic effects of glucocorticoids,
particularly in severe asthma patients who are usually
treated with ﬂuctuating doses of systemic glucocorticoids.
In patients with diabetes mellitus treated with insulin,
the use of glucocorticoids is usually associated with a
proportional increase in the units of insulin needed to
control serum glucose levels.11
We report the case of a corticosteroid-insensitive severe
asthma patient who was also an insulin-dependent diabetic.
By monitoring the needs of insulin doses on a daily basis, we
compared the systemic effects of prednisone and TA. We
also evaluated the response of asthma to prednisone and TA
through daily monitoring of PEF, as well as through the
assessment of clinical symptoms and the use of short-acting
b2-agonist agents as rescue medication.Case report
A 56-year-old man was referred to the Severe Asthma Clinic
of our Institution for evaluation. Asthma has developed at
the age of 39 with the characteristics of a severe process.
Exacerbations occurred frequently, triggered by respiratoryinfections, physical activity, cold air, and exposure to
irritants (paints, smoke). Attacks often occurred at night
or in early morning. He had a chronic morning cough that
produced scanty clear secretions. He had visited the
emergency department on many occasions and had been
admitted to hospital ﬁve times, but never to the intensive
care unit. The patient has never smoked, had no history of
allergy and the prick test to common allergens was negative.
He was followed by a specialist in pulmonary medicine
and treated with ﬂuticasone (1000 mg/day), salmeterol
(100 mg/day), montelukast (10mg/day), and oral prednisone
(daily doses ﬂuctuating between 10 and 70mg). He often
used salbutamol as rescue medication and was also provided
with a nebulizer to self-administer at home a combination of
salbutamol and ipratropium bromide that he has used
regularly (ranging from 2 to 6 nebulizations daily).
The patient had a history of diabetes mellitus that began
at the age of 18 and treated with insulin (Unilong 375, Lilly,
Spain; mean daily dose 40 units, ranging from 30 to 70
units). He presented various common complications asso-
ciated with diabetes mellitus including: diabetic retino-
pathy, and erectile and urinary blander dysfunction. He had
required laser therapy four times to treat the retinopathy.
He also suffered from arterial hypertension treated with
enalapril maleate.
The patient appeared to be compliant with respect to the
medication and he used inhalers adequately. He had a
normal weight for his height, gender and age, and he had a
mild cushingoid face appearance.
The patient was followed up in the out-patient clinic and
the presence of the comorbidities sometimes associated
with refractory asthma (cardiac insufﬁciency, gastroesopha-
geal reﬂux, and obstruction of the upper airway), was
excluded. The patient remained symptomatic with daily
symptoms, frequent night awakening and regular use of
bronchodilator therapy. The daily dose of prednisone
ranged from 10 to 60mg. With high doses of prednisone
(60–70mg/day), the symptoms appeared to slightly improve
but when the dose of prednisone was tapered below
25–20mg, they worsened again and the patients had to
use nebulized bronchodilator therapy 5–6 times a day. Daily
PEF measurements showed values from 150 to 230 L/m
changing in parallel to variations in the oral dose of
prednisone.
A bone mineral densitometric (BMD) study showed a spine
osteopenia (BMD ¼ 0.979 g/cm2; T-score ¼ 2.0; normal
values T-scoreX1.0).
To check the adequate use of medication and the
response to glucocorticoids, the patient was admitted to
hospital and treated with 70mg of prednisone (1mg/kg of
weight) for 4 days, and the dose was progressively tapered
by 10mg every 3 days. The patient was discharged on day
ten and followed up in the out-patient clinic. The morning
PEF slowly improved from a baseline value of 160 L/m to a
maximal of 230 with glucocorticoid therapy, but the
improvement slowed down when the dose of oral prednisone
was progressively tapered (Figure 1). The forced expiratory
volume in the 1 s (FEV1), rose from a baseline value of 54% of
predicted to a maximal value of 63% predicted. Clinical
symptoms followed a similar pattern to that of PEF, with an
initial improvement followed by a progressive deterioration
when the dose of prednisone was reduced. When the patient
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Figure 2 Change in insulin doses (units) and morning PEF
(L/m/10) from four consecutive injections of 40mg of triamci-
nolone acetonide (TA), repeated every 6 weeks. Values are
expressed as mean7SD. PEF ¼ peak expiratory ﬂow.
Figure 3 Change in insulin doses (units) and morning PEF
(L/m/10) during a burst of oral prednisone. PEF ¼ peak
expiratory ﬂow.
Figure 1 Changes in morning PEF (L/m) with a burst of
prednisone followed by an intramuscular injection of 40mg of
triamcinolone acetonide (TA). PEF ¼ peak expiratory ﬂow.
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40mg of TA was administered and prednisone was discon-
tinued. A dramatic and rapid increase in morning PEF was
observed, rising from 150 L/m up to 420 L/m. The FEV1 went
to up to 80% predicted from a baseline value of 57%
predicted. There was a marked improvement in symptoms
during the day and at night. The therapeutic effects of TA
lasted for almost 4 weeks; after that period the PEF began
to decline and the symptoms also restarted with nasal
obstruction, productive cough, shortness of breath and night
awakenings (Figure 1). After 4 weeks of occasional use of
rescue medication, the patient had to take additional puffs
of salbutamol almost daily.
A second injection of TA produced the same results and it
was decided to maintain the patient on regular therapy with
this drug. The patient has been followed up for 3 years.
During this period he has received injections of TA repeated
at intervals ranging from 21 to 60 days according to patient
response and the evolution of PEF and clinical symptoms. All
his other therapy (ﬂuticasone, salmeterol, and montelukast)
remained unchanged. He has not attended the emergency
department and has not been hospitalized within this 3-year
period.
In a routine control, the patient’s ophthalmologist found a
dramatic improvement in the proliferative diabetic retino-
pathy, with completed resolution of macular oedema
and signiﬁcant improvement in visual acuity. A BMD study
after 1 year of TA therapy showed a 7.8% increase in BMD
(1.063 g/cm2; T-score ¼ 1.5).
The monitoring of changes in daily insulin doses and PEF
values was used to assess and compare the systemic effects
and therapeutic efﬁcacy of triamcinolone and prednisone.
Figure 2 shows the mean change in insulin doses and morning
PEF from four consecutive injections of TA repeated every 6
weeks. The insulin doses were increased immediately after
the injection and progressively reduced until approximately
the 18th day, and after that no more signiﬁcant changes
were observed. The PEF also steadily increased by reaching
the maximal value around the third week. The PEF begun to
decline around the fourth week and the decrease acceler-
ated during the sixth week. Clinical symptoms usually
reappeared within the fourth and ﬁfth week. The sequenceof clinical events almost always followed the same pattern:
ﬁrst, nasal obstruction, and rhinorrhea; second, cough, and
bronchial secretions, and ﬁnally, shortness of breath and
night awakenings.
Figure 3 shows the change in morning PEF and insulin
doses during a burst of oral prednisone, started at 1mg/kg
of weight (70mg/day) for 4 days and then progressively
tapered 10mg every 3–4 days. There was an increase in the
insulin doses in parallel to the increase in prednisone. The
PEF also increased, but much less than with the injection of
triamcinolone (Figure 2). If we take the doses of insulin as a
marker of the systemic effect of the two glucocorticoids,
and the changes in PEF as a measure of the efﬁcacy of the
therapies, the ratio of efﬁcacy vs systemic side effects is
clearly in favour of TA (Figures 2 and 3).
The effects of an injection of TA and a burst of prednisone
on insulin doses are shown and compared in Figure 4. The
maximal effect of TA appears to be equivalent to that
exerted by 50–60mg of prednisone, while the effect of TA on
insulin in the ﬁfth and the sixth week, when its efﬁcacy
began to decline, seems to be close to that caused by 5mg
of prednisone.
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Figure 4 Comparative study of the effects of an intramuscular
injection of 40mg of triamcinolone acetonide (TA) and a burst
of prednisone on insulin doses (units).
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The patient herein presented is representative of a small
percentage in the whole asthma population, but he is not so
rare in those specialized asthma clinics to which difﬁcult-to-
control asthma patients are usually referred. Despite the
use of the most potent inhaled glucocorticoids associated
with long-acting b2-agonist bronchodilators and antileuko-
triene drugs, these patients need regular treatment and/or
frequent short courses of oral glucocorticoids. In some of
these patients the response to systemic glucocorticoids is
even poor or null (steroid-resistant asthma). Previous
studies, and this case report, show that the injection of TA
is very effective in asthma patients who do not respond to
high doses of prednisone.2–9
Whether the higher efﬁcacy of TA is due to improved
compliance, improved anti-inﬂammatory effects or both is a
matter of debate. The use of TA is also questioned on the
basis of the unacceptable toxicity that its use may cause.10
Intramuscular TA’s ratio of clinical efﬁcacy to systemic
effects compared with oral prednisone has not been clearly
deﬁned. Various validated and standardized methods are
available to easily and continuously monitor the pharmaco-
logical effects of antiasthma drugs, such as PEF measure-
ment, scoring of symptoms and quantiﬁcation of the needs
of rescue medication. However, there are no similar tools
available to closely and regularly assess the systemic effects
of glucocorticoids in patients submitted to ﬂuctuating doses
of the drugs. Even more complicated is the comparative
study of different glucocorticoids with disparate pharmaco-
kinetic proﬁles such as prednisone and TA. The peak plasma
concentration of TA occurs within 8–48 h of injection, after
which there is a steady decrease, with the drug being
undetectable in plasma after 21 days12 In contrast, oral
prednisone is rapidly absorbed across the gastrointestinal
membrane. Peak effects can be observed after 1–2 h.
Prednisone is metabolized by the liver to the active
metabolite prednisolone, which is then metabolized to
inactive compounds. The plasma elimination half-life is
1 h, whereas the biological half-life of prednisone is
18–36 h.13The diabetic condition of the glucocorticoid-resistant
asthmatic presented in this case report, allowed us to daily
monitor the systemic effect on a daily basis using the well-
known effect of glucocorticoids on insulin doses. The use of
PEF and its correlation with the changes in clinical
symptoms also enabled us to compare the therapeutic
efﬁcacy of the two glucocorticoids. The analysis of the
balance between systemic effects (insulin doses) and
salutary effects (PEF values), presented in Figures 1 and 2,
shows that TA has a better beneﬁt/risk proﬁle than
prednisone.
The higher anti-inﬂammatory potency of TA compared to
prednisone is also supported by the observed improvement
in diabetic retinopathy when the patient started TA therapy.
While the patient was on prednisone, he needed laser
therapy several times; this treatment was no longer used in
the 3-year follow-up period of observation during which he
was on TA. This ﬁnding concurs with recent reports in the
ophthalmology literature on the success of intravitreal
administration of TA in the treatment of diabetic retino-
pathy apparently resistant to other glucocorticoids.14
Why could a single 4–6 weekly dose of TA improve control
in a patient with a prednisone-resistant asthma? The change
from oral to intramuscular administration was considered to
account for the improvement in symptoms, lung function
and sputum eosinophilia in a group of asthma patients not
responding to oral prednisone who were treated with one
single dose of 40mg of TA.8 Surprisingly, in the interpreta-
tion of the results, the authors did not take into account
that they have changed not only the route, but also the
glucocorticoid. The authors did not mention any of the
previously reported studies on the use of TA in severe
asthma, despite the fact that this option has been discussed
by various researchers for over 20 years.2–7,9
Although the reason(s) why TA is more effective than
prednisone in severe asthma are as yet unclear, most
probably the pharmacological proﬁle of TA could account,
al least in part, for its greater anti-inﬂammatory potency.
Perhaps continuous exposure of inﬂammatory cells to TA is
more effective than the short contact to intermittent doses
of prednisone.
The patient’s 3-year follow-up also illustrates the good
tolerability of TA. During this period the patient lost 3 kg of
weight, his BMD increased, his arterial tension normalized
and treatment with enalapril maleate could be discontin-
ued. These observations concur with previous reports
showing signiﬁcant fall in weight and improvement in
hypertension control in patients on TA with respect to the
period on prednisone therapy.7,9 Previous studies have also
shown that reduction of the glucocorticoid dose may result
in a partial recovery of the lost BMD.15 Our ﬁndings suggest
that treatment with TA caused less deleterious effects on
bone mineralization than prednisone therapy.
However, not all patients tolerate TA so well, and
muscular atrophy, menstrual irregularities and hirsutism
have been reported in patients repeatedly treated with
doses of TA higher than 40mg and/or for periods shorter
than 4–5 weeks.6,7 The patient reported herein developed
bruising and skin fragility that resulted in frequent skin
lacerations caused by minor trauma. Skin atrophy is one of
the main side effects observed with TA therapy in
comparison with prednisone treatment. There is no clear
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exerted by TA on weight, hypertension, and bone miner-
alization compared to skin atrophy. Skin atrophy has been
observed with ﬂuorinated glucocorticoids administered by
all routes (inhaled, systemic, and topical)16,17 but the
mechanisms involved in varying intensities of the systemic
side effects of these drugs on different tissues and organs
are as yet unclear.
In summary, intramuscular TA proved to be effective in a
prednisone-resistant asthma patient. By assessing changes in
insulin doses it was possible to closely monitor and compare
the systemic side effects of TA and prednisone, two drugs
with very different pharmacokinetic proﬁles. The analysis of
the balance between systemic effects (insulin doses) and
therapeutic effects (PEF values) shows that TA has a better
beneﬁt/risk proﬁle than prednisone. In addition, some
prednisone-associated side effects decreased during the
3-year follow-up treatment with TA. All in all, these ﬁndings
suggest that TA can be a potentially valuable alternative in
the control of some severe, prednisone-resistant asthma.
Elucidation of the mechanisms by which TA is more
effective than prednisone in some severe asthmatics might
help to better understand the origin of glucocorticoid
resistance and could also contribute to the design of
powerful new drugs to treat these patients, who are usually
difﬁcult to manage.
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